CoChat
Sign Up
Cited by 957

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Ageing and neuronal vulnerability

Mattson, Mark P., Magnus, Tim·2006·Nature Reviews Neuroscience
DOI 10.1038/nrn1886
Open this paper in CoChat — free account

Abstract

Everyone ages, but only some will develop a neurodegenerative disorder in the process. Disease might occur when cells fail to respond adaptively to age-related increases in oxidative, metabolic and ionic stress, thereby resulting in the accumulation of damaged proteins, DNA and membranes. Determinants of neuronal vulnerability might include cell size and location, metabolism of disease-specific proteins and a repertoire of signal transduction pathways and stress resistance mechanisms. Emerging evidence on protein interaction networks that monitor and respond to the normal ageing process suggests that successful neural ageing is possible for most people, but also cautions that cures for neurodegenerative disorders are unlikely in the near future.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrn1886

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Neuroinflammation can directly damage neurons, impair synaptic plasticity, and disrupt neuronal networks, leading to cognitive decline and functional impairments.

    “Neuroinflammation can directly damage neurons, impair synaptic plasticity, and disrupt neuronal networks, leading to cognitive decline and functional impairments5–7.”

    From MT1-MMP inhibition rejuvenates ageing brain and rescues cognitive deficits in obesity (2025) · cites this paper as [6]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 212

  1. Hofer, S. M., Berg, S. & Era, P. Evaluating the interdependence of aging-related changes in visual and auditory acuity, balance, and cognitive functioning. Psychol. Aging 18, 285–305 (2003). · DOI
  2. Mattson, M. P. Pathways towards and away from Alzheimer's disease. Nature 430, 631–639 (2004). This review integrates information on the molecular pathogenesis of AD and efforts to prevent and treat this disorder. · DOI · Paper page
  3. Cookson, M. R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29–52 (2005). · DOI
  4. Moore, D. J., West, A. B., Dawson, V. L. & Dawson, T. M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 27, 57–87 (2005). Reviews the involvement of mitochondrial dysfunction and perturbed ubiquitin-mediated proteolysis in PD. · DOI
  5. Sieradzan, K. A. & Mann, D. M. The selective vulnerability of nerve cells in Huntington's disease. Neuropathol. Appl. Neurobiol. 27, 1–21 (2001). · DOI
  6. Cleveland, D. W. & Rothstein, J. D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nature Rev. Neurosci. 2, 806–819 (2001). · DOI
  7. Serrano, F. & Klann, E. Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res. Rev. 3, 431–443 (2004). · DOI
  8. Zecca, L., Youdim, M. B., Riederer, P., Connor, J. R. & Crichton, R. R. Iron, brain ageing and neurodegenerative disorders. Nature Rev. Neurosci. 5, 863–873 (2004). · DOI · Paper page
  9. Ames, B. N. Delaying the mitochondrial decay of aging. Ann. NY Acad. Sci. 1019, 406–411 (2004). · DOI
  10. Gray, D. A., Tsirigotis, M. & Woulfe, J. Ubiquitin, proteasomes, and the aging brain. Sci. Aging Knowledge Environ. RE6 27 Aug 2003. · DOI
  11. Trojanowski, J. Q. & Mattson, M. P. Overview of protein aggregation in single, double, and triple neurodegenerative brain amyloidoses. Neuromolecular Med. 4, 1–6 (2003). · DOI
  12. Kyng, K. J. & Bohr, V. A. Gene expression and DNA repair in progeroid syndromes and human aging. Ageing Res. Rev. 4, 579–602 (2005). · DOI · Paper page
  13. Butler, R. N. et al. Longevity genes: from primitive organisms to humans. J. Gerontol. A Biol. Sci. Med. Sci. 58, 581–584 (2003). · DOI
  14. Wolkow, C. A. Life span: getting the signal from the nervous system. Trends Neurosci. 25, 212–216 (2002). Describes how insulin-like signalling in the nervous system might regulate ageing and determine lifespan. · DOI
  15. Mattson, M. P. Methylation and acetylation in nervous system development and neurodegenerative disorders. Ageing Res. Rev. 2, 329–342 (2003). · DOI
  16. Yehuda, S., Rabinovitz, S., Carasso, R. L. & Mostofsky, D. I. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol. Aging 23, 843–853 (2002). · DOI
  17. Floyd, R. A. & Hensley, K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol. Aging 23, 795–807 (2002). · DOI
  18. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53, S26–S36 (2003). · DOI · Paper page
  19. Pedersen, W. A. et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann. Neurol. 44, 819–824 (1998). · DOI
  20. Rakhit, R. et al. Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J. Biol. Chem. 279, 15499–15504 (2004). · DOI
  21. Grondin, R. et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125, 2191–2201 (2002). · DOI
  22. Zuccato, C. et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genet. 35, 76–83 (2003). · DOI · Paper page
  23. Weindruch, R. & Sohal, R. S. Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N. Engl. J. Med. 337, 986–994 (1997). · DOI
  24. Heilbronn, L. K. & Ravussin, E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am. J. Clin. Nutr. 78, 361–369 (2003). · DOI · Paper page
  25. Mattison, J. A., Lane, M. A., Roth, G. S. & Ingram, D. K. Calorie restriction in rhesus monkeys. Exp. Gerontol. 38, 35–46 (2003). · DOI
  26. Fontana, L., Meyer, T. E., Klein, S. & Holloszy, J. O. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl Acad. Sci. USA 101, 6659–6663 (2004). · DOI · Paper page
  27. Mattson, M. P. Energy intake, meal frequency, and health: a neurobiological perspective. Annu. Rev. Nutr. 25, 237–260 (2005). · DOI
  28. Patel, N. V. et al. Caloric restriction attenuates Aβ-deposition in Alzheimer transgenic models. Neurobiol. Aging 26, 995–1000 (2005). · DOI · Paper page
  29. Maswood, N. et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc. Natl Acad. Sci. USA 101, 18171–18176 (2004). · DOI
  30. Yu, Z. F. & Mattson, M. P. Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J. Neurosci. Res. 57, 830–839 (1999). · DOI
  31. Mattson, M. P., Maudsley, S. & Martin, B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 27, 589–594 (2004). · DOI · Paper page
  32. Barja, G. Free radicals and aging. Trends Neurosci. 27, 595–600 (2004). · DOI · Paper page
  33. Cotman, C. W. & Berchtold, N. C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 25, 295–301 (2002). · DOI · Paper page
  34. Spires, T. L. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J. Neurosci. 24, 2270–2276 (2004). · DOI
  35. Liu, D. et al. Mitochondrial UCP4 induces a glycolytic shift in energy metabolism and increases the resistance of neurons to oxidative stress. Neuromolecular Med. (in the press).
  36. Parker, J. A. et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nature Genet. 37, 349–350 (2005). · DOI
  37. Morrison, B. M., Hof, P. R. & Morrison, J. H. Determinants of neuronal vulnerability in neurodegenerative diseases. Ann. Neurol. 44, S32–S44 (1998). · DOI
  38. Smith, D. E., Saji, M., Joh, T. H., Reis, D. J. & Pickel, V. M. Ibotenic acid-induced lesions of striatal target and projection neurons: ultrastructural manifestations in dopaminergic and non-dopaminergic neurons and in glia. Histol. Histopathol. 2, 251–263 (1987).
  39. Mandelkow, E. M., Stamer, K., Vogel, R., Thies, E. & Mandelkow, E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 24, 1079–1085 (2003). · DOI
  40. Bayatti, N. & Behl, C. The neuroprotective actions of corticotropin releasing hormone. Ageing Res. Rev. 4, 258–270 (2005). · DOI
  41. Ishunina, T. A. & Swaab, D. F. Neurohypophyseal peptides in aging and Alzheimer's disease. Ageing Res. Rev. 1, 537–558 (2002). · DOI
  42. Braak, H. & Braak, E. Evolution of neuronal changes in the course of Alzheimer's disease. J. Neural Transm. Suppl. 53, 127–140 (1998). · DOI
  43. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211 (2003). · DOI · Paper page
  44. Mills, K. R. The natural history of central motor abnormalities in amyotrophic lateral sclerosis. Brain 126, 2558–2566 (2003). · DOI
  45. Yuan, J. & Yankner, B. A. Apoptosis in the nervous system. Nature 407, 802–809 (2000). Reviews evidence that supports a role for apoptosis in the pathogenesis of neurodegenerative disorders. · DOI
  46. Miller, F. D., Pozniak, C. D. & Walsh, G. S. Neuronal life and death: an essential role for the p53 family. Cell Death Differ. 7, 880–888 (2000). · DOI
  47. Tanaka, Y. et al. Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10, 919–926 (2001). · DOI
  48. Akhtar, R. S., Ness, J. M. & Roth, K. A. Bcl-2 family regulation of neuronal development and neurodegeneration. Biochim. Biophys. Acta 1644, 189–203 (2004). · DOI
  49. Cheung, E. C. et al. Apoptosis-inducing factor is a key factor in neuronal cell death propagated by BAX-dependent and BAX-independent mechanisms. J. Neurosci. 25, 1324–1334 (2005). · DOI
  50. Wang, K. K. Calpain and caspase: can you tell the difference? Trends Neurosci. 23, 20–26 (2000). · DOI
  51. Stefanis, L. Caspase-dependent and -independent neuronal death: two distinct pathways to neuronal injury. Neuroscientist 11, 50–62 (2005). · DOI
  52. Chan, S. L. et al. Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12. Neurobiol. Dis. 11, 2–19 (2002). · DOI
  53. Brown, D. & Tatton, N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol. 53 (Suppl. 3), S61–S70 (2003).
  54. Crocker, S. J. et al. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci. 23, 4081–4091 (2003). · DOI
  55. Gafni, J. & Ellerby, L. M. Calpain activation in Huntington's disease. J. Neurosci. 22, 4842–4849 (2002). · DOI
  56. Friedlander, R. M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 348, 1365–1375 (2003). · DOI
  57. Mattson, M. P. & Kroemer, G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol. Med. 9, 196–205 (2003). · DOI
  58. Glazner, G. W. et al. Endoplasmic reticulum D-myo-inositol 1,4,5-trisphosphate-sensitive stores regulate nuclear factor-κB binding activity in a calcium-independent manner. J. Biol. Chem. 276, 22461–22467 (2001). · DOI
  59. Milhavet, O. et al. Involvement of Gadd153 in the pathogenic action of presenilin-1 mutations. J. Neurochem. 83, 673–681 (2002). · DOI
  60. Boehning, D. et al. Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nature Cell Biol. 5, 1051–1061 (2003). · DOI
  61. Culmsee, C. & Mattson, M. P. p53 in neuronal apoptosis. Biochem. Biophys. Res. Commun. 331, 761–777 (2005). · DOI
  62. Kruman, I. et al. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J. Neurosci. 17, 5089–5100 (1997). · DOI
  63. Bruckner, S. R., Perry, G. & Estus, S. 4-hydroxynonenal contributes to NGF withdrawal-induced neuronal apoptosis. J. Neurochem. 85, 999–1005 (2003). · DOI
  64. Zhou, H., Li, X. M., Meinkoth, J. & Pittman, R. N. Akt regulates cell survival and apoptosis at a postmitochondrial level. J. Cell Biol. 151, 483–494 (2000). · DOI
  65. Cutler, R. G. et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, 2070–2075 (2004). Links age-related alterations in the metabolism of membrane lipids to oxidative stress and neuronal degeneration in AD. · DOI · Paper page
  66. Haughey, N. J. et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann. Neurol. 55, 257–267 (2004). · DOI
  67. Cutler, R. G. et al. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol. 52, 448–457 (2002). · DOI
  68. White, L. D. & Barone, S. Jr Qualitative and quantitative estimates of apoptosis from birth to senescence in the rat brain. Cell Death Differ. 8, 345–356 (2001). · DOI
  69. Hiona, A. & Leeuwenburgh, C. Life-long caloric restriction counteracts apoptotic effects of aging in the brain and bolsters the action of apoptosis inhibitors. Neurobiol. Aging. 26 Sep 2006 (doi: 10.1016/j.neurobiolaging.2005.08.006). · DOI
  70. Kempermann, G., Kuhn, H. G. & Gage, F. H. Experience-induced neurogenesis in the senescent dentate gyrus. J. Neurosci. 18, 3206–3212 (1998). Evidence that age-related declines in hippocampal neurogenesis can be counteracted by cognitive stimulation. · DOI · Paper page
  71. Sun, W. et al. Programmed cell death of adult-generated hippocampal neurons is mediated by the proapoptotic gene Bax. J. Neurosci. 24, 11205–11213 (2004). · DOI
  72. Haughey, N. J. et al. Disruption of neurogenesis by amyloid β-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J. Neurochem. 83, 1509–1524 (2002). · DOI · Paper page
  73. Jin, K. et al. Increased hippocampal neurogenesis in Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, 343–347 (2004). · DOI · Paper page
  74. Mattson, M. P. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med. 3, 65–94 (2003). · DOI
  75. Ben-Ari, Y. & Cossart, R. Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci. 23, 580–587 (2000). · DOI
  76. Perl, T. M. et al. An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N. Engl. J. Med. 323, 1631–1633 (1990). · DOI
  77. Kisby, G. E., Ellison, M. & Spencer, P. S. Content of the neurotoxins cycasin (methylazoxymethanol β-D-glucoside) and BMAA (β-N-methylamino-L-alanine) in cycad flour prepared by Guam Chamorros. Neurology 42, 1336–1340 (1992). · DOI
  78. Langston, J. W., Ballard, P., Tetrud, J. W. & Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979–980 (1983). First direct evidence that an environmental neurotoxin can cause parkinsonism. · DOI · Paper page
  79. Panov, A. et al. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J. Biol. Chem. 280, 42026–42035 (2005). · DOI · Paper page
  80. Ludolph, A. C., He, F., Spencer, P. S., Hammerstad, J. & Sabri, M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18, 492–498 (1991). · DOI
  81. Berridge, M. J., Bootman, M. D. & Roderick, H. L. Calcium signalling: dynamics, homeostasis and remodelling. Nature Rev. Mol. Cell Biol. 4, 517–529 (2003). · DOI
  82. Toescu, E. C., Verkhratsky, A. & Landfield, P. W. Ca2+ regulation and gene expression in normal brain aging. Trends Neurosci. 27, 614–620 (2004). · DOI
  83. Guo, Q. et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nature Med. 5, 101–106 (1999). · DOI · Paper page
  84. Schneider, I. et al. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J. Biol. Chem. 276, 11539–11544 (2001). · DOI
  85. Martinez, J., Moeller, I., Erdjument-Bromage, H., Tempst, P. & Lauring, B. Parkinson's disease-associated α-synuclein is a calmodulin substrate. J. Biol. Chem. 278, 17379–17387 (2003). · DOI
  86. Tang, T. S. et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl Acad. Sci. USA 102, 2602–2607 (2005). · DOI
  87. Smith, R. G. et al. Altered muscle calcium channel binding kinetics in autoimmune motoneuron disease. Muscle Nerve 18, 620–627 (1995). · DOI
  88. Von Lewinski, F. & Keller, B. U. Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci. 28, 494–500 (2005). · DOI
  89. Mattson, M. P., Rychlik, B., Chu, C. & Christakos, S. Evidence for calcium-reducing and excito-protective roles for the calcium-binding protein calbindin-D28k in cultured hippocampal neurons. Neuron 6, 41–51 (1991). · DOI
  90. Magloczky, Z. & Freund, T. F. Selective neuronal death in the contralateral hippocampus following unilateral kainate injections into the CA3 subfield. Neuroscience 56, 317–335 (1993). · DOI
  91. Guela, C. et al. Loss of calbindin-D28k from aging human cholinergic basal forebrain: relation to neuronal loss. J. Comp. Neurol. 455, 249–259 (2003). · DOI
  92. Thorns, V., Licastro, F. & Masliah, E. Locally reduced levels of acidic FGF lead to decreased expression of 28-kDa calbindin and contribute to the selective vulnerability of the neurons in the entorhinal cortex in Alzheimer's disease. Neuropathology 21, 203–211 (2001). · DOI
  93. Iacopino, A. M. & Christakos, S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc. Natl Acad. Sci. USA 87, 4078–4082 (1990). Evidence that age- and neuron-specific changes in calcium-binding proteins are associated with SNV. · DOI
  94. Alexianu, M. E. et al. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. 36, 846–858 (1994). · DOI
  95. Ikonomovic, M. D. et al. Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer's disease. Exp. Neurol. 160, 194–204 (1999). · DOI
  96. Williams, T. L., Day, N. C., Ince, P. G., Kamboj, R. K. & Shaw, P. J. Calcium-permeable α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. 42, 200–207 (1997). · DOI
  97. Melov, S. Modeling mitochondrial function in aging neurons. Trends Neurosci. 27, 601–606 (2004). · DOI
  98. Petit-Taboue, M. C., Landeau, B., Desson, J. F., Desgranges, B. & Baron, J. C. Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping. Neuroimage 7, 176–184 (1998). · DOI · Paper page
  99. Masconi, L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32, 486–510 (2005). · DOI
  100. Dagher, A. Functional imaging in Parkinson's disease. Semin. Neurol. 21, 23–32 (2001). · DOI
  101. Feigin, A. et al. Metabolic network abnormalities in early Huntington's disease: an [18F]FDG PET study. J. Nucl. Med. 42, 1591–1595 (2001).
  102. Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P. & Gibson, G. E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 57, 695–703 (2005). · DOI · Paper page
  103. Smigrodzki, R., Parks, J. & Parker, W. D. High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol. Aging 25, 1273–1281 (2004). · DOI
  104. Seong, I. S. et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14, 2871–2880 (2005). · DOI
  105. Manfredi, G. & Xu, Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion 5, 77–87 (2005). · DOI
  106. Brown, M. R., Geddes, J. W. & Sullivan, P. G. Brain region-specific, age-related, alterations in mitochondrial responses to elevated calcium. J. Bioenerg. Biomembr. 36, 401–406 (2004). · DOI
  107. Murchison, D., Zawieja, D. C. & Griffith, W. H. Reduced mitochondrial buffering of voltage-gated calcium influx in aged rat basal forebrain neurons. Cell Calcium 36, 61–75 (2004). · DOI
  108. Kim, G. W. & Chan, P. H. Oxidative stress and neuronal DNA fragmentation mediate age-dependent vulnerability to the mitochondrial toxin, 3-nitropropionic acid, in the mouse striatum. Neurobiol. Dis. 8, 114–126 (2001). Evidence that neuronal vulnerability to mitochondrial toxins increases with advancing age. · DOI
  109. Patel, J. R. & Brewer, G. J. Age-related changes in neuronal glucose uptake in response to glutamate and β-amyloid. J. Neurosci. Res. 72, 527–536 (2003). · DOI
  110. Klivenyi, P. et al. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J. Neurosci. 20, 1–7 (2000). · DOI · Paper page
  111. Keller, J. N. et al. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J. Neurosci. 18, 687–697 (1998). · DOI · Paper page
  112. Bruce-Keller, A. J., Umberger, G., McFall, R. & Mattson, M. P. Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann. Neurol. 45, 8–15 (1999). · DOI
  113. Duan, W. & Mattson, M. P. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. Res. 57, 195–206 (1999). · DOI
  114. Niwa, K., Kazama, K., Younkin, S. G., Carlson, G. A. & Iadecola, C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9, 61–68 (2002). · DOI · Paper page
  115. Keller, J. N. et al. Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. J. Neurosci. 18, 4439–4450 (1998). · DOI
  116. Guo, Q., Christakos, S., Robinson, N. & Mattson, M. P. Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function. Proc. Natl Acad. Sci. USA 95, 3227–3232 (1998). · DOI
  117. Trushina, E. et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell Biol. 24, 8195–8209 (2004). · DOI · Paper page
  118. Klivenyi, P. et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med. 5, 347–350 (1999). · DOI · Paper page
  119. Tarnopolsky, M. A. & Beal, M. F. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. 49, 561–574 (2001). Reviews evidence that a cellular energy deficit has a key role in the degeneration of motor neurons in HD and ALS. · DOI
  120. Szweda, P. A., Camouse, M., Lundberg, K. C., Oberley, T. D. & Szweda, L. I. Aging, lipofuscin formation, and free radical-mediated inhibition of cellular proteolytic systems. Ageing Res. Rev. 2, 383–405 (2003). · DOI
  121. Gray, D. A. & Woulfe, J. Lipofuscin and aging: a matter of toxic waste. Sci. Aging Knowledge Environ. RE1 2 Feb 2005. · DOI
  122. Nixon, R. A. The calpains in aging and aging-related diseases. Ageing Res. Rev. 2, 407–418 (2003). · DOI
  123. Bi, X., Yong, A. P., Zhou, J., Gall, C. M. & Lynch, G. Regionally selective changes in brain lysosomes occur in the transition from young adulthood to middle age in rats. Neuroscience 97, 395–404 (2000). · DOI
  124. Keller, J. N., Hanni, K. B. & Markesbery, W. R. Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mech. Ageing Dev. 113, 61–70 (2000). · DOI
  125. Lam, Y. A. et al. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 9902–9906 (2000). · DOI
  126. McNaught, K. S., Olanow, C. W., Halliwell, B., Isacson, O. & Jenner, P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nature Rev. Neurosci. 2, 589–594 (2001). · DOI · Paper page
  127. Sullivan, P. G. et al. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J. Biol. Chem. 279, 20699–20707 (2004). · DOI
  128. Bednarski, E., Ribak, C. E. & Lynch, G. Suppression of cathepsins B and L causes a proliferation of lysosomes and the formation of meganeurites in hippocampus. J. Neurosci. 17, 4006–4021 (1997). · DOI
  129. Nixon, R. A. et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 64, 113–122 (2005). · DOI · Paper page
  130. Bergamini, E., Cavallini, G., Donati, A. & Gori, Z. The anti-ageing effects of caloric restriction may involve stimulation of macroautophagy and lysosomal degradation, and can be intensified pharmacologically. Biomed. Pharmacother. 57, 203–208 (2003). · DOI
  131. Maggio, J. E. et al. Reversible in vitro growth of Alzheimer disease β-amyloid plaques by deposition of labeled amyloid peptide. Proc. Natl Acad. Sci. USA 89, 5462–5466 (1992). · DOI
  132. Petkova, A. T. et al. Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307, 262–265 (2005). Shows that subtle variations in the environment of pathogenic peptides modifies their self-propagating and neurotoxic properties. · DOI · Paper page
  133. Tanzi, R. E., Moir, R. D. & Wagner, S. L. Clearance of Alzheimer's Aβ peptide: the many roads to perdition. Neuron 43, 605–608 (2004).
  134. Goedert, M. Tau gene mutations and their effects. Mov. Disord. 12, S45–S52 (2005). · DOI
  135. Stoothoff, W. H. & Johnson, G. V. Tau phosphorylation: physiological and pathological consequences. Biochim. Biophys. Acta 1739, 280–297 (2005). · DOI
  136. Montine, T. J., Amarnath, V., Martin, M. E., Strittmatter, W. J. & Graham, D. G. E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. Am. J. Pathol. 148, 89–93 (1996).
  137. Moore, D. J., West, A. B., Dawson, V. L. & Dawson, T. M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57–87 (2005). · DOI
  138. Singleton, A. B. et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003). The first evidence that a modest increase in the production of α-synuclein is sufficient to cause PD. · DOI · Paper page
  139. Yavich, L., Tanila, H., Vepsalainen, S. & Jakala, P. Role of α-synuclein in presynaptic dopamine recruitment. J. Neurosci. 24, 11165–11170 (2004). · DOI
  140. Bates, G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361, 1642–1644 (2003). · DOI
  141. Fox, J. H. et al. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 91, 413–422 (2004). · DOI
  142. Wyttenbach, A. et al. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 11, 1137–1151 (2002). · DOI
  143. Giffard, R. G. et al. Chaperones, protein aggregation, and brain protection from hypoxic/ischemic injury. J. Exp. Biol. 207, 3213–3220 (2004). · DOI
  144. Cohen, F. E. & Kelly, J. W. Therapeutic approaches to protein-misfolding diseases. Nature 426, 905–909 (2003). · DOI
  145. Zhao, L., Longo-Guess, C., Harris, B. S., Lee, J. W. & Ackerman, S. L. Protein accumulation and neurodegeneration in the woozy mutant mouse is caused by disruption of SIL1, a cochaperone of BiP. Nature Genet. 37, 974–979 (2005). · DOI
  146. Rousseau, E. et al. Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation. Proc. Natl Acad. Sci. USA 101, 9648–9653 (2004). · DOI
  147. Kieran, D. et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nature Med. 10, 402–405 (2004). Pharmacological induction of protein chaperones results in therapeutic benefit in a mouse model of ALS. · DOI
  148. Siegel, G. J. & Chauhan, N. B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Rev. 33, 199–227 (2000). · DOI
  149. Dore, S., Kar, S. & Quirion, R. Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity. Proc. Natl Acad. Sci. USA 94, 4772–4777 (1997). · DOI
  150. Counts, S. E. & Mufson, E. J. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J. Neuropathol. Exp. Neurol. 64, 263–272 (2005). · DOI
  151. Gash, D. M., Zhang, Z. & Gerhardt, G. Neuroprotective and neurorestorative properties of GDNF. Ann. Neurol. 44, S121–S125 (1998). · DOI
  152. Ross, C. A. Huntington's disease: new paths to pathogenesis. Cell 118, 4–7 (2004). · DOI
  153. Wilczak, N. & de Keyser, J. Insulin-like growth factor system in amyotrophic lateral sclerosis. Endocr. Dev. 9, 160–169 (2005). · DOI
  154. Hattiangady, B., Rao, M. S., Shetty, G. A. & Shetty, A. K. Brain-derived neurotrophic factor, phosphorylated cyclic AMP response element binding protein and neuropeptide Y decline as early as middle age in the dentate gyrus and CA1 and CA3 subfields of the hippocampus. Exp. Neurol. 195, 353–371 (2005). · DOI
  155. Gooney, M., Messaudi, E., Maher, F. O., Bramham, C. R. & Lynch, M. A. BDNF-induced LTP in dentate gyrus is impaired with age: analysis of changes in cell signaling events. Neurobiol. Aging 25, 1323–1331 (2004). · DOI
  156. Monti, B., Berteotti, C. & Contestabile, A. Dysregulation of memory-related proteins in the hippocampus of aged rats and their relation with cognitive impairment. Hippocampus 15, 1041–1049 (2005). · DOI
  157. Adlard, P. A., Perreau, V. M. & Cotman, C. W. The exercise-induced expression of BDNF within the hippocampus varies across life-span. Neurobiol. Aging 26, 511–520 (2005). · DOI · Paper page
  158. Yurek, D. M. & Fletcher-Turner, A. Lesion-induced increase of BDNF is greater in the striatum of young versus old rat brain. Exp. Neurol. 161, 392–396 (2000). · DOI
  159. Dore, S., Kar, S., Rowe, W. & Quirion, R. Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. Neuroscience 80, 1033–1040 (1997). · DOI
  160. D'Costa, A. P., Xu, X., Ingram, R. L. & Sonntag, W. E. Insulin-like growth factor-1 stimulation of protein synthesis is attenuated in cerebral cortex of aging rats. Neuroscience 65, 805–813 (1995). · DOI
  161. Woods, A. G., Guthrie, K. M., Kurlawalla, M. A. & Gall, C. M. Deafferentation-induced increases in hippocampal insulin-like growth factor-1 messenger RNA expression are severely attenuated in middle aged and aged rats. Neuroscience 83, 663–668 (1998). Evidence that the capacity of brain cells to increase neurotrophic factor signalling is impaired during ageing. · DOI
  162. Sonntag, W. E., Ramsey, M. & Carter, C. S. Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res. Rev. 4, 195–212 (2005). · DOI
  163. Grondin, R. et al. Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J. Neurosci. 23, 1974–1980 (2003). · DOI
  164. Martinez-Serrano, A., Fischer, W. & Bjorklund, A. Reversal of age-dependent cognitive impairments and cholinergic neuron atrophy by NGF-secreting neural progenitors grafted to the basal forebrain. Neuron 15, 473–484 (1995). The authors show that it is possible to recover age-dependent cognitive deficits by transplantation of neurotrophic factor-producing cells into the basal forebrain. · DOI
  165. Lopez-Lopez, C., LeRoith, D. & Torres-Aleman, I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc. Natl Acad. Sci. USA 101, 9833–9838 (2004). · DOI · Paper page
  166. Murer, M. G., Yan, Q. & Raisman-Vozari, R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 63, 71–124 (2001). · DOI · Paper page
  167. Scott, S. A. & Crutcher, K. A. Nerve growth factor and Alzheimer's disease. Rev. Neurosci. 5, 179–211 (1994). · DOI
  168. Zuccato, C. et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493–498 (2001). The first evidence that mutant huntingtin perturbs transcriptional regulation of neurotrophic factor production. · DOI · Paper page
  169. Duan, W. et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann. Neurol. 55, 590–594 (2004). · DOI
  170. Dehmelt, L. & Halpain, S. The MAP2/Tau family of microtubule-associated proteins. Genome Biol. 6, 204 (2005). · DOI · Paper page
  171. Al-Chalabi, A. & Miller, C. C. Neurofilaments and neurological disease. Bioessays 25, 346–355 (2003). · DOI
  172. Trojanowski, J. Q. & Lee, V. M. The role of tau in Alzheimer's disease. Med. Clin. North Am. 86, 615–627 (2002). · DOI · Paper page
  173. Norris, E. H. & Giasson, B. I. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders. Antioxid. Redox Signal. 7, 672–684 (2005). · DOI
  174. O'Neill, C. et al. Dysfunctional intracellular calcium homoeostasis: a central cause of neurodegeneration in Alzheimer's disease. Biochem. Soc. Symp. 67, 177–194 (2001). · DOI
  175. Gauthier, L. R. et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127–138 (2004). · DOI · Paper page
  176. Zhang, B., Tu, P., Abtahian, F. & Trojanowski, J. Q. Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J. Cell Biol. 139, 1307–1315 (1997). Reports direct evidence that a mutation that causes ALS impairs axonal transport in motor neurons. · DOI
  177. Ishihara, T. et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24, 751–762 (1999). · DOI · Paper page
  178. Brandt, R., Hundelt, M. & Shahani, N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim. Biophys. Acta 1739, 331–354 (2005). · DOI
  179. McGeer, P. L. & McGeer, E. G. Local neuroinflammation and the progression of Alzheimer's disease. J. Neurovirol. 8, 529–538 (2002). · DOI
  180. Dickson, D. W., Lee, S. C., Mattiace, L. A., Yen, S. H. & Brosnan, C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7, 75–83 (1993). · DOI
  181. Eikelenboom, P., Hack, C. E., Rozemuller, J. M. & Stam, F. C. Complement activation in amyloid plaques in Alzhiemer's dementia. Virchows Arch. 56, 259–262 (1989). · DOI
  182. Nath, A. et al. Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer's disease patients and Aβ antibodies can enhance Aβ neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med. 3, 29–39 (2003). · DOI
  183. Teismann, P. & Schulz, J. B. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res. 318, 149–161 (2004). · DOI
  184. Sargsyan, S. A., Monk, P. N. & Shaw, P. J. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia 51, 241–253 (2005). · DOI
  185. Smith, R. G. et al. Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. Proc. Natl Acad. Sci. USA 91, 3393–3397 (1994). · DOI
  186. Miller, R. G., Mitchell, J. D., Lyon, M. & Moore, D. H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph. Lateral Scler. Other Motor Neuron Disord. 4, 191–206 (2003). · DOI
  187. Reisberg, B. et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch. Neurol. 63, 49–54 (2006). · DOI
  188. Wang, J. et al. Caloric restriction attenuates β-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J. 19, 659–661 (2005). · DOI
  189. Lazarov, O. et al. Environmental enrichment reduces Aβ levels and amyloid deposition in transgenic mice. Cell 120, 701–713 (2005). Reports the first evidence that exercise/cognitive stimulation can enhance clearance of Aβ from the brain. · DOI · Paper page
  190. Lim, G. P. et al. A diet enriched with the ω-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25, 3032–3040 (2005). · DOI
  191. DeKosky, S. T. Statin therapy in the treatment of Alzheimer disease: what is the rationale? Am. J. Med. 118, S48–S53 (2005). · DOI
  192. Lipton, S. A. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J. Alzheimers Dis. 6, S61–S74 (2004). · DOI · Paper page
  193. Duan, W. et al. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol. 52, 597–606 (2002). · DOI
  194. Bae, B. I. et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47, 29–41 (2005). · DOI
  195. Ellis, A. C. & Rosenfeld, J. The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders. CNS Drugs 18, 967–980 (2004). · DOI
  196. Kordower, J. H. et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767–773 (2000). Reports the efficacy of gene therapy in a non-human primate model of PD. · DOI
  197. Dobrowolny, G. et al. Muscle expression of a local IGF-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 168, 193–199 (2005). · DOI
  198. Levy, Y. S., Gilgun-Sherki, Y., Melamed, E. & Offen, D. Therapeutic potential of neurotrophic factors in neurodegenerative diseases. BioDrugs 19, 97–127 (2005). · DOI
  199. Gelinas, D. S., DaSilva, K., Fenili, D., St Georger-Hyslop, P. & McLaurin, J. Immunotherapy for Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, S14657–S14662 (2004). · DOI
  200. Harper, S. Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl Acad. Sci. USA 102, 5820–5825 (2005). · DOI · Paper page

200 of 212 shown

Cited by

Sorted by citations

Metadata

Authors
Mattson, M. P., & Magnus, T.
Venue
Nature Reviews Neuroscience
Publisher
Springer Science and Business Media LLC
Published
2006-04
Volume
7
Issue
4
Pages
278-294
ISSN
  • 1471-003X
  • 1471-0048
DOI
10.1038/nrn1886
Cited by
957
References
14
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review